A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world

Previously, we have reported short term effectiveness and safety of dupilumab in Korea. In this study, we are trying to report the long-term effectiveness and safety of dupilumab in Korea. Ninety-nine patients with moderate to severe AD were analyzed. They were evaluated using Eczema Area and Severity Index (EASI), Numerical Rating Scale (NRS), Patient Oriented Eczema Measure (POEM), and Dermatology Quality of Life Index (DLQI) at baseline, week 16, 32 and 52. Efficacy outcomes showed higher improvement at 52 weeks compared with 16 weeks; high percentual reductions in EASI (88.1%), peak pruritus NRS (65.6%), POEM (67.2%), and DLQI (69.0%) compared to baseline. Proportion of patients achieving EASI 75 and 90 were 90.2% and 53.7%. POEM and DLQI had high correlation with clinical measured outcomes. In the analysis for the factors affecting achievement of EASI 90, female gender (OR 2.5), eosinophilia (OR 0.2) and elevated LDH (OR 0.07) were significantly associated. Most frequent adverse events included facial erythema (19.2%) and conjunctivitis (17.2%), which were mild/moderate and resolved during treatment. In conclusion, dupilumab treatment for 52 weeks in Korean patients with moderate-to-severe AD confirmed long term effectiveness and safety.

Skin Adverse Reactions to Novel Messenger RNA Coronavirus Vaccination: A Case Series

Vaccines are actually the most effective strategy to control the COVID-19 spread and reduce mortality, but adverse reactions can occur. Skin involvement with novel messenger RNA coronavirus vaccines seems frequent but is not completely characterized. A real-world experience in the recent vaccination campaign among health care workers in Sardinia (Italy) is reported. In over a total of 1577 persons vaccinated, 9 cases of skin adverse reactions were observed (0.5%). All reactions have been reported to the Italian Pharmacovigilance Authority. Eight occurred in women (mean age 46 years), and five were physicians and four nurses. All patients had a significant allergology history but not for the known vaccine excipients. After dose one, no injection site reactions were observed, but widespread pruritus (n = 3), mild facial erythema (n = 1), and maculopapular rash (n = 3) occurred in the following 24–48 h in three patients. These three patients were excluded from the second dose. Of the remaining six patients, one developed mild anaphylaxis within the observation period at the vaccination hub and five delayed facial erythematous edema and maculopapular lesions, requiring antihistamines and short-course corticosteroid treatment. Spontaneous reporting is paramount to adjourning vaccination guidance and preventive measures in order to contribute to the development of a safe vaccine strategy. Dermatologist’ expertise might provide better characterization, treatment, and screening of individuals at high risk of skin adverse reactions.

Aspects of classification and diagnostic search for transient and persistent facial erythema

Розацеа – одно из наиболее частых заболеваний кожи лица. Клиническая картина розацеа характеризуется покраснением центральных частей лица, приливами, телеангиэктазиями, реже папулами и пустулами, фиматозными проявлениями. С покраснением кожи лица сталкиваются дерматологи, аллергологи, терапевты, семейные врачи. В типичных случаях диагностика розацеа не вызывает затруднений, однако покраснением кожи лица и приливами может сопровождаться множество заболеваний, как доброкачественных, так и злокачественных. Большинство случаев вызваны очень распространенными доброкачественными заболеваниями, такими как розацеа, которые легко диагностируются после тщательного сбора анамнеза и осмотра. Однако в некоторых случаях точный диагноз требует дальнейших лабораторных, радиологических или гистопатологических исследований. Например, карциноидный синдром, феохромоцитому, системный мастоцитоз, дерматомиозит, системную красную волчанку, анафилаксию необходимо исключить лабораторными исследованиями. В статье приведены основные заболевания, которые необходимо учитывать при диагностике транзиторной или постоянной эритемы при розацеа. Rosacea is one of the most common conditions on the face. Rosacea affecting the central parts of the face and is characterized by erythema, flushing, telangiectasia; papules and pustules. Cutaneous flushing – a common presenting complaint to dermatologists, allergists, internists, and family practitioners. Diagnosis typical cases of rosacea is not difficult, but many diseases, both benign and malignant, can be associated with facial flushing and erythema. Most cases are caused by very common, benign diseases, such as rosacea, that are readily apparent after a thorough taking of history and physical examination. However, in some cases, accurate diagnosis requires further laboratory, radiologic, or histopathologic studies. In particular, the serious diagnoses of carcinoid syndrome, pheochromocytoma, mastocytosis, systemic lupus erythematosus, dermatomyositisand anaphylaxis need to be excluded by laboratory studies. In the article, we present main diseases that dermatologysts should consider when diagnosing rosacea.

Steroid-induced Rosacea- A Study From a Tertiary Care Hospital of Eastern Nepal

Introduction: Topical corticosteroids (TC) are useful for treatment of various dermatological conditions in all age groups. Due to its cosmetic application TCs misuse is intertwined with fairness creams in our colour conscious society where people are obsessed with fair colour. Aims and Objectives: To find the clinical presentations of steroid induced rosacea like-dermatitis on the face and to evaluate the purpose behind misusing TCs on the face. Materials and methods: Descriptive prospective questionnaire-type case series study was approved by Institutional Ethical Committee of BPKIHS which involved 205 patients diagnosed as Steroid Induced Rosacea who consulted Dermatology OPD between March to June 2017. Results: Among 205 patients enrolled, majority were from second to fourth decade (87.31%) of their life and maximum being females I.e. 91.2%. Around 97% of the study population were unaware of side effects of TCs. Most patients use Mometasone fuorate (58.04%) for melisma (88.29%). Friends acted as source of prescription (29.75%), followed by Pharmacist (24.88%) & Beauty centers (20%). Dermatologists prescribed TCs in only 6.34% cases. Sun exposure was identified as the triggering factor for steroid induced rosacea in 73.17% patients. Cheek was the commonest site involve in 92.19%, followed by forehead (65.36%), perioral area (46.83%), and chin (9.75%). Mixed type of lesions was the commonest lesion found in 52.20% patients, followed by diffuse facial erythema (36.09%), & telangiectasia (33.17%). Conclusion: TCs misuse in the younger people for the sake of fairer skin with little or no knowledge about the adverse effects of this medication should be stopped.